Primary Biliary Cirrhosis

    The data set found in appendix D of Fleming and Harrington, Counting
Processes and Survival Analysis, Wiley, 1991.  The only differences are:
     age is in days
     status is coded as 0=censored, 1=censored due to liver tx, 2=death
     the sex and stage variables are not missing for obs 313-418

Quoting from F&H.  "The following pages contain the data from the Mayo Clinic
trial in primary biliary cirrhosis (PBC) of the liver conducted between 1974
and 1984.  A description of the clinical background for the trial and the
covariates recorded here is in Chapter 0, especially Section 0.2.  A more
extended discussion can be found in Dickson, et al., Hepatology 10:1-7 (1989)
and in Markus, et al., N Eng J of Med 320:1709-13 (1989).

   "A total of 424 PBC patients, referred to Mayo Clinic during that ten-year
interval, met eligibility criteria for the randomized placebo controlled
trial of the drug D-penicillamine.  The first 312 cases in the data set
participated in the randomized trial and contain largely complete data.  The
additional 112 cases did not participate in the clinical trial, but consented
to have basic measurements recorded and to be followed for survival.  Six of
those cases were lost to follow-up shortly after diagnosis, so the data here
are on an additional 106 cases as well as the 312 randomized participants.
Missing data items are denoted by `.'. "

Variables:
   case number
   number of days between registration and the earlier of death,
       transplantion, or study analysis time in July, 1986
   status
   drug: 1= D-penicillamine, 2=placebo
   age in days
   sex: 0=male, 1=female
   presence of asictes:       0=no 1=yes
   presence of hepatomegaly   0=no 1=yes
   presence of spiders        0=no 1=yes
   presence of edema          0=no edema and no diuretic therapy for edema;
    .5 = edema present without diuretics, or edema resolved by diuretics;
    1 = edema despite diuretic therapy
   serum bilirubin in mg/dl
   serum cholesterol in mg/dl
   albumin in gm/dl
   urine copper in ug/day
   alkaline phosphatase in U/liter
   SGOT in U/ml
   triglicerides in mg/dl
   platelets per cubic ml / 1000
   prothrombin time in seconds
   histologic stage of disease


                                                     A                P
       F             A H S                 A         L                L    P
       U S           S E P                 L    C    K                A    R
       _ T           C P I  E              B    O    _                T    O  S
       D A D         I A D  D     B   C    U    P    P       S    T   E    T  T
       A T R   A   S T T E  E     I   H    M    P    H       G    R   L    I  A
  I    Y U U   G   E E O R  M     L   O    I    E    O       O    I   E    M  G
  D    S S G   E   X S M S  A     I   L    N    R    S       T    G   T    E  E

  1  400 2 1 21464 1 1 1 1 1.0 14.5  261 2.60 156  1718.0 137.95 172 190 12.2 4
  2 4500 0 1 20617 1 0 1 1 0.0  1.1  302 4.14  54  7394.8 113.52  88 221 10.6 3
  3 1012 2 1 25594 0 0 0 0 0.5  1.4  176 3.48 210   516.0  96.10  55 151 12.0 4

etc...

416 1055 0 . 20819 1 . . . 0.0  1.6    . 3.42   .      .     .     . 143  9.9 3
417  691 0 . 21185 1 . . . 0.0  0.8    . 3.75   .      .     .     . 269 10.4 3
418  976 0 . 19358 1 . . . 0.0  0.7    . 3.29   .      .     .     . 350 10.6 4